Clinical trial · Observational
Early Detection of Prostate Cancer by FACS
NCT00524823CI-TRIAL-00000860FACSunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Early detection of prostrate cancer and development of metastases. The research will attempt to match the SCM test (structuredness of the cytoplasmic matrix) in lymphocytes as an early cancer detection test using Florescent Activated Cell Sorting (FACS) as a replacement for the CellScan instrument. The test is based on measurement of cellular changes in response to the specific prostate antigen, PSA.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hyperplasia | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (4)
- label
- 1
- description
- 10 diagnosed men in age 60 - 90 with Prostate Cancer
- label
- 2
- description
- 10 patients with benign growth
- label
- 3
- description
- 10 health volunteers
- label
- 4
- description
- 10 patients diagnosed with other cancer
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 60 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: Experimental group : Males between the ages of 60-90 years, with medical diagnosis of prostate cancer according to both clinical and hematological examinations, before receiving any medical treatment. Control Group 1: Males between the ages of 60-90 years, with diagnosed benign prostate hyperplasia -BPH. Control Group 2: Males between the ages of 60-90 years, medically diagnosed as healthy. Control Group 3: Males between the ages of 60-90 years, medically diagnosed with another form of cancer, not prostate. Exclusion Criteria: Experimental group: Other known cancer or systemic infection. Control Group 1: Other known cancer or systemic infection. Control Group 2:Past hematological disorders nor cancer growth history. other known systemic infection, nor urinary tract infection. Patients hospitalized for orthopedic injuries of any type who are otherwise free of urinary tract infections. Control Group 3:Other known systemic infection, nor urinary tract infection. \-
References
Publications (4)
- BACKGROUNDKlein O, Lin S, Embon O, Sazbon A, Zidan J, Kook AI. An approach for high sensitivity detection of prostate cancer by analysis of changes in structuredness of the cytoplasmic matrix of lymphocytes specifically induced by PSA-ACT. J Urol. 1999 Jun;161(6):1994-6. PMID 10332488
- BACKGROUNDAltman, Roberta. The prostate Answer Book. Warner Books, lnc., 1993.
- BACKGROUNDAmerican Cancer Society. National Cnference on Prostate Cancer. Philadelphia, Pennsylvania: September/October 1994.
- BACKGROUNDRous, Stephen N., M.D.; The prostate Book. W.W. Norton & Co., 1992.